XNASVAXX
Market cap38kUSD
Dec 20, Last price
0.00USD
1D
50.00%
1Q
-99.40%
IPO
-100.00%
Name
Vaxxinity Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-57k
L-99.92%
CFO
-57m
L+2.34%
Earnings
Mar 25, 2025
Profile
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 66 -88.15% | ||||
Cost of revenue | 58,285 | 77,663 | 125,141 | ||
Unusual Expense (Income) | |||||
NOPBT | (58,285) | (77,663) | (125,075) | ||
NOPBT Margin | |||||
Operating Taxes | (57) | (12) | 840 | ||
Tax Rate | |||||
NOPAT | (58,228) | (77,651) | (125,915) | ||
Net income | (57) -99.92% | (75,210) -45.51% | (138,015) 290.13% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 454 | 263 | 71,077 | ||
BB yield | -422.20% | -0.15% | -10.10% | ||
| Debt | |||||
Debt current | 1,906 | 1,504 | 376 | ||
Long-term debt | 13,262 | 13,045 | 10,323 | ||
Deferred revenue | (236) | ||||
Other long-term liabilities | 35 | 236 | 1,000 | ||
Net debt | (15,332) | (72,278) | (134,358) | ||
| Cash flow | |||||
Cash from operating activities | (57,238) | (55,928) | (80,990) | ||
CAPEX | (803) | (1,866) | (1,318) | ||
Cash from investing activities | 28,844 | (54,392) | (1,318) | ||
Cash from financing activities | (1,140) | (167) | 196,167 | ||
FCF | (56,797) | (77,791) | (126,129) | ||
| Balance | |||||
Cash | 30,500 | 86,827 | 144,885 | ||
Long term investments | 172 | ||||
Excess cash | 30,500 | 86,827 | 145,054 | ||
Stockholders' equity | (361,351) | (304,622) | (229,203) | ||
Invested Capital | 389,963 | 381,348 | 368,522 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 127 | 125,939 | 125,392 | ||
Price | 0.85 -39.29% | 1.40 -75.04% | 5.61 | ||
Market cap | 108 -99.94% | 176,315 -74.94% | 703,450 | ||
EV | (15,224) | 104,037 | 569,092 | ||
EBITDA | (56,051) | (75,979) | (123,973) | ||
EV/EBITDA | 0.27 | ||||
Interest | 696 | 514 | 840 | ||
Interest/NOPBT | |||||